Lineage Cell Therapeutics, Inc. (LCTX) Presents at H.C. Wainwright twenty seventh

Sara Nik
Analysis Analyst

And welcome to our subsequent session. I am the moderator, Sara Nik, an Fairness Analysis VP at H.C. Wainwright. And it is my pleasure to introduce our subsequent presenter, Brian Culley, CEO of Lineage Cell Therapeutics, a scientific stage biotechnology firm creating novel cell therapies for neurological and ophthalmic situations. Brian, the ground is yours.

Brian Culley
CEO, President & Director

Thanks a lot, and good morning, all people. It is a pleasure to be right here. All proper. Subsequent slide. In order we’re a publicly traded firm and I’ll make some forward-looking statements, please consult with our secure harbor info filed at scientific trials — excuse me, that was ironic — sec.gov. You may as well go to clinicaltrials.gov.

All proper. So Lineage Cell Therapeutics. I’ll go in a short time as we speak as a result of I need to squeeze in a few new issues that you have not heard offered from the corporate earlier than. We had some bulletins. However as a basic matter, Lineage Cell Therapeutics is devoted to the manufacture and supply of particular cell varieties. And we’re doing this in an effort to deal with situations and indications the place the lack of a sure cell sort provides rise to the illness. The very best and greatest use case for this thus far for us has been within the setting of dry age-related macular degeneration. This illness, the hallmark is the lack of RPE cells. We manufacture RPE cells within the laboratory and ship them to sufferers in an effort to restore the operate that is misplaced in that situation.

The pipeline, that is